CD274 and lung carcinoma: Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated lung cancer or breast cancer and also showed clinical benefit when combined with chemotherapy as first-line treatment of lung cancer or breast cancer (78, 79).